{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:52:46Z","timestamp":1785189166231,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bioethical Inquiry"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:italic>Background <\/jats:italic>Psychedelic medicine is a rapidly growing area of research and policy change. Australia recently became the first country to legalize the prescription of psychedelics and serves as a case study of issues that may emerge in other jurisdictions. Despite their influence as a stakeholder group, there has been little empirical exploration of psychedelic researchers\u2019 views on the development of psychedelic research and the ethical concerns. <jats:italic>Methods<\/jats:italic> We thematically analysed fourteen interviews with Australian psychedelic researchers. <jats:italic>Results<\/jats:italic> Three themes were constructed from the data: 1) coming out of the shadow of the 1960s, 2) challenges and affordances in engaging stakeholders, and 3) growing pains in innovation and translation. <jats:italic>Conclusion<\/jats:italic> The results illustrated tensions arising from the rapid growth of psychedelic research from a small group of dedicated individuals with a similar worldview, to a multi-interest, regulated industry. Participants\u2019 experiences and viewpoints were influenced by the history of psychedelic research, and this was met with an overarching concern for protecting the field from premature discontinuation, as well as maximizing potential positive impacts. Targets for stakeholder collaboration and initiatives to support responsible innovation in psychedelics include equitable access, sustainable industry involvement, productive research agendas, responsible reporting of evidence, and risk-taking within the relative safety of clinical trials.<\/jats:p>","DOI":"10.1007\/s11673-024-10386-4","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T09:01:50Z","timestamp":1728032510000},"page":"327-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-6905","authenticated-orcid":false,"given":"Michaela","family":"Barber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"6","key":"10386_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","volume":"239","author":"JS Aday","year":"2022","unstructured":"Aday, J.S., B.D. Heifets, S.D. Pratscher, E. Bradley, R. Rosen, and J.D. Woolley. 2022. Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology 239(6): 1989\u20132010.","journal-title":"Psychopharmacology"},{"issue":"2","key":"10386_CR2","doi-asserted-by":"publisher","first-page":"e12959","DOI":"10.1111\/soc4.12959","volume":"16","author":"T Andrews","year":"2022","unstructured":"Andrews, T., and K. Wright. 2022. The frontiers of new psychedelic therapies: A survey of sociological themes and issues. Sociology Compass 16(2): e12959.","journal-title":"Sociology Compass"},{"issue":"7929","key":"10386_CR3","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1038\/d41586-022-02875-6","volume":"609","author":"PS Appelbaum","year":"2022","unstructured":"Appelbaum, P.S. 2022. Psychedelic research and the real world.\u00a0Nature\u00a0609(7929): S95.","journal-title":"Nature"},{"issue":"6","key":"10386_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/NMD.0000000000000828","volume":"206","author":"BS Barnett","year":"2018","unstructured":"Barnett, B.S., W.O. Siu, and H. G Pope, Jr. 2018. A survey of American psychiatrists\u2019 attitudes toward classic hallucinogens.\u00a0The Journal of Nervous and Mental Disease\u00a0206(6): 476\u2013480.","journal-title":"The Journal of Nervous and Mental Disease"},{"key":"10386_CR5","doi-asserted-by":"publisher","first-page":"100202","DOI":"10.1016\/j.ssmqr.2022.100202","volume":"3","author":"M Barber","year":"2023","unstructured":"Barber, M., J. Gardner, and A. Carter. 2023. Transformative agents of change and investigative neurotechnologies: A qualitative study of psychedelic technology identities. SSM \u2013 Qualitative Research in Health 3: 100202.","journal-title":"SSM \u2013 Qualitative Research in Health"},{"issue":"3","key":"10386_CR6","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1503\/jpn.220090","volume":"47","author":"SL Borgland","year":"2022","unstructured":"Borgland, S.L., and D.M. Neyens. 2022. Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies.\u00a0Journal of Psychiatry & Neuroscience\u00a047(3): E218\u2013E221.","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"10386_CR7","unstructured":"Blau, A., and G. Thompson. 2023. \u201cSerious concerns\u201d over TGA\u2019s decision making on landmark psilocybin, MDMA ruling. Australian Broadcasting Corporation, March 18. https:\/\/www.abc.net.au\/news\/2023-03-18\/psychedelic-charity-accused-lobbying-tga-mdma-psilocybin\/102103782. Accessed July 31, 2023."},{"issue":"4","key":"10386_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun, V., and V. Clarke. 2019. Reflecting on reflexive thematic analysis. Qualitative Research in Sport, Exercise and Health 11(4): 589\u2013597.","journal-title":"Qualitative Research in Sport, Exercise and Health"},{"key":"10386_CR9","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s11135-021-01182-y","volume":"56","author":"D Byrne","year":"2022","unstructured":"Byrne, D. 2022. A worked example of Braun and Clarke\u2019s approach to reflexive thematic analysis. Quality & Quantity 56: 1391\u20131412.","journal-title":"Quality & Quantity"},{"issue":"11","key":"10386_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R.L., and G.M. Goodwin. 2017. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 42(11): 2105\u20132113.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10386_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/23299460.2019.1692571","volume":"7","author":"M Carrier","year":"2020","unstructured":"Carrier, M., and M. Gartzlaff. 2020. Responsible research and innovation: Hopes and fears in the scientific community in Europe. Journal of Responsible Innovation 7(2): 149\u2013169.","journal-title":"Journal of Responsible Innovation"},{"key":"10386_CR12","doi-asserted-by":"publisher","first-page":"887255","DOI":"10.3389\/fpsyg.2022.887255","volume":"13","author":"M Cavarra","year":"2022","unstructured":"Cavarra, M., A. Falzone, J.G. Ramaekers, K.P.C Kuypers, and C. Mento. 2022. Psychedelic-assisted psychotherapy\u2014A systematic review of associated psychological interventions. Frontiers in Psychology 13: 887255.","journal-title":"Frontiers in Psychology"},{"key":"10386_CR13","doi-asserted-by":"crossref","unstructured":"Celidwen, Y., N. Redvers, C. Githaiga, et al. 2023. Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice.\u00a0Lancet Regional Health Americas\u00a018: 100410.","DOI":"10.1016\/j.lana.2022.100410"},{"key":"10386_CR14","unstructured":"Chrysanthos, N. 2023. \u2018It\u2019s going to be for people with money\u2019: Psychedelic treatments tipped to cost at least $25,000. The Sydney Morning Herald, March 21. https:\/\/www.smh.com.au\/politics\/federal\/it-s-going-to-be-for-people-with-money-psychedelic-treatments-tipped-to-cost-at-least-25-000-at-first-20230313-p5crpd.html. Accessed July 31, 2023."},{"key":"10386_CR15","doi-asserted-by":"publisher","first-page":"108610","DOI":"10.1016\/j.neuropharm.2021.108610","volume":"193","author":"V Chiu","year":"2021","unstructured":"Chiu, V., J. Leung, W. Hall, D. Stjepanovi\u0107, and L. Degenhardt, L. 2021. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology 193: 108610.","journal-title":"Neuropharmacology"},{"key":"10386_CR16","doi-asserted-by":"publisher","first-page":"e006928","DOI":"10.1136\/bmjgh-2021-006928","volume":"6","author":"E Colman","year":"2021","unstructured":"Colman,\u00a0E., M. Wanat, H. Goossens, S. Tonkin-Crine, and S. Anthierens. 2021. Following the science? Views from scientists on government advisory boards during the COVID-19 pandemic: a qualitative interview study in five European countries. BMJ Global Health 6: e006928.","journal-title":"BMJ Global Health"},{"key":"10386_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12910-015-0010-3","volume":"16","author":"R Davies","year":"2015","unstructured":"Davies, R.,J. Ives, and M. Dunn. 2015. A systematic review of empirical bioethics methodologies. BMC Medical Ethics 16: 15.","journal-title":"BMC Medical Ethics"},{"issue":"4","key":"10386_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2021.1971343","volume":"54","author":"AK Davis","year":"2022","unstructured":"Davis, A.K., G. Agin-Liebes, M. Espa\u00f1a, B. Pilecki, and J. Luoma. 2022. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States.\u00a0Journal of Psychoactive Drugs\u00a054(4): 309\u2013318.","journal-title":"Journal of Psychoactive Drugs"},{"key":"10386_CR19","doi-asserted-by":"publisher","DOI":"10.1353\/book.3470","volume-title":"Psychedelic psychiatry: LSD from clinic to campus","author":"E Dyck","year":"2008","unstructured":"Dyck, E. 2008. Psychedelic psychiatry: LSD from clinic to campus. Baltimore: Johns Hopkins University Press."},{"issue":"August","key":"10386_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugpo.2019.05.019","volume":"70","author":"J Gardner","year":"2019","unstructured":"Gardner, J., A. Carter, K. O\u2019Brien, and K. Seear. 2019. Psychedelic-assisted therapies: The past, and the need to move forward responsibly. International Journal of Drug Policy 70(August): 94\u201398.","journal-title":"International Journal of Drug Policy"},{"issue":"1","key":"10386_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1556\/2054.2019.015","volume":"4","author":"JR George","year":"2020","unstructured":"George, J.R., T.I. Michaels, J. Sevelius, and M.T. Williams. 2020. The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion.\u00a0Journal of Psychedelic Studies\u00a04(1): 4\u201315.","journal-title":"Journal of Psychedelic Studies"},{"key":"10386_CR22","first-page":"12068","volume":"365","author":"T Greenhalgh","year":"2019","unstructured":"Greenhalgh, T., and C. Papoutsi. 2019. Spreading and scaling up innovation and improvement. BMJ 365: 12068.","journal-title":"BMJ"},{"key":"10386_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1057\/s41292-020-00208-2","volume":"17","author":"CJ Guerrini","year":"2022","unstructured":"Guerrini, C.J., M. Trejo, I. Canfield, and A.L. McGuire. 2022. Core values of genomic citizen science: results from a qualitative interview study. BioSocieties 17: 203\u2013228.","journal-title":"BioSocieties"},{"issue":"11","key":"10386_CR24","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1111\/add.15560","volume":"116","author":"W Hall","year":"2021","unstructured":"Hall, W., and M. Farrell. 2021. What can we learn from the history of research on psychedelic drugs in the addictions? Addiction 116(11): 2936\u20132938.","journal-title":"Addiction"},{"issue":"14","key":"10386_CR25","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1017\/S0033291722003191","volume":"52","author":"WD Hall","year":"2022","unstructured":"Hall, W.D., and K. Humphreys. 2022. Is good science leading the way in the therapeutic use of psychedelic drugs? Psychological Medicine 52(14): 2849\u20132851.","journal-title":"Psychological Medicine"},{"key":"10386_CR26","doi-asserted-by":"crossref","unstructured":"Haridy, R. 2023. Australia to prescribe MDMA and psilocybin for PTSD and depression in world first. Nature, June 30.","DOI":"10.1038\/d41586-023-02093-8"},{"issue":"4","key":"10386_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcad.12429","volume":"100","author":"BG Hearn","year":"2022","unstructured":"Hearn, B.G., M.D. Brubaker, and G. Richardson. 2022. Counselors\u2019 attitudes toward psychedelics and their use in therapy. Journal of Counseling and Development 100(4): 364\u2013373.","journal-title":"Journal of Counseling and Development"},{"key":"10386_CR28","volume-title":"LSD\u2014My Problem Child","author":"A Hoffman","year":"1980","unstructured":"Hoffman, A. 1980. LSD\u2014My Problem Child. New York: McGraw-Hill."},{"issue":"7","key":"10386_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276","volume":"37","author":"OR Hovmand","year":"2023","unstructured":"Hovmand, O.R., E.D. Poulsen, S. Arnfred, and O.J. Storeb\u00f8. 2023. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. Journal of Psychopharmacology 37(7): 649\u2013659.","journal-title":"Journal of Psychopharmacology"},{"key":"10386_CR30","unstructured":"Jeffries, D. 2022. Colorado just legalized \u2018magic mushrooms,\u2019 an idea that\u2019s growing nationwide. National Broadcasting Corporation, November 12. https:\/\/www.nbcnews.com\/data-graphics\/magic-mushrooms-psilocybin-map-colorado-us-states-rcna55980. Accessed July 31, 2023"},{"issue":"1","key":"10386_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/02698811221133461","volume":"37","author":"B Kious","year":"2022","unstructured":"Kious, B., Z. Schwartz, Z and B. Lewis. 2022. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. Journal of Psychopharmacology 37(1): 45\u201348.","journal-title":"Journal of Psychopharmacology"},{"issue":"7","key":"10386_CR32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs, T.S., and P.\u00d8. Johansen. 2012. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology 26(7): 994\u20131002.","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"10386_CR33","first-page":"92","volume":"3","author":"G Laudel","year":"2007","unstructured":"Laudel, G., and J. Gl\u00e4ser. 2007. Interviewing scientists. Science, Technology & Innovation Studies 3(2): 92\u2013111.","journal-title":"Science, Technology & Innovation Studies"},{"issue":"2","key":"10386_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1080\/23299460.2018.1434739","volume":"5","author":"M Loro\u00f1o-Leturiondo","year":"2018","unstructured":"Loro\u00f1o-Leturiondo, M., and S.R. Davies. 2018. Responsibility and science communication: Scientists \u2018experiences of and perspectives on public communication activities. Journal of Responsible Innovation 5(2): 170\u2013185.","journal-title":"Journal of Responsible Innovation"},{"issue":"4","key":"10386_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000522603","volume":"28","author":"J McCambridge","year":"2022","unstructured":"McCambridge, J., and G. Mitchell. 2022. The views of researchers on the alcohol industry\u2019s involvement in science: Findings from an interview study. European Addiction Research 28(4): 267\u2013274.","journal-title":"European Addiction Research"},{"issue":"6643","key":"10386_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1126\/science.adg1324","volume":"480","author":"AL McGuire","year":"2023","unstructured":"McGuire, A.L., H. Fernandez-Lynch, L.A. Grossman, and I.G. Cohen. 2023. Pressing regulatory challenges for psychedelic medicine. Science 480(6643): 347\u2013350.","journal-title":"Science"},{"issue":"5","key":"10386_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","volume":"80","author":"S McNamee","year":"2023","unstructured":"McNamee, S., N. Devenot, and M. Buisson. 2023. Studying harms is key to improving psychedelic-assisted therapy\u2014Participants call for changes to research landscape.\u00a0JAMA Psychiatry\u00a080(5): 411\u2013412.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10386_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels, T.I., J. Purdon, A. Collins, and M.T. Williams. 2018. Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature.\u00a0BMC Psychiatry\u00a018(1): 245.","journal-title":"BMC Psychiatry"},{"key":"10386_CR39","doi-asserted-by":"crossref","unstructured":"Mihalopoulos, C., C. Langmead, and M. L. Chatterton. 2023. The tricky economics of subsidising psychedelics for mental health therapy. The Conversation, May 1. https:\/\/theconversation.com\/the-tricky-economics-of-subsidising-psychedelics-for-mental-health-therapy-201462. Accessed July 31, 2023.","DOI":"10.64628\/AA.xe9vtrh3a"},{"issue":"6","key":"10386_CR40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J.M., M. Bogenschutz, A. Lilienstein, et al. 2021. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.\u00a0Nature Medicine\u00a027(6): 1025\u20131033.","journal-title":"Nature Medicine"},{"issue":"10","key":"10386_CR41","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell, J. M., G. M. Ot\u2019alora, B. van der Kolk, et al. 2023. MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine 29(10): 2473\u20132480.","journal-title":"Nature Medicine"},{"issue":"9","key":"10386_CR42","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy, S.D., A. Forsyth, and T. Lumley. 2021. Blinding and expectancy confounds in psychedelic randomized controlled trials.\u00a0Expert Review of Clinical Pharmacology\u00a014(9): 1133\u20131152.","journal-title":"Expert Review of Clinical Pharmacology"},{"issue":"1","key":"10386_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1556\/2054.2019.018","volume":"4","author":"T Noorani","year":"2020","unstructured":"Noorani, T. 2020. Making psychedelics into medicines: The politics and paradoxes of medicalization. Journal of Psychedelic Studies 4(1): 34\u201339.","journal-title":"Journal of Psychedelic Studies"},{"issue":"9566","key":"10386_CR44","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","volume":"369","author":"D Nutt","year":"2007","unstructured":"Nutt, D., L.A. King, W. Saulsbury, and C. Blakemore. 2007. Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 369(9566): 1047\u20131053.","journal-title":"The Lancet"},{"key":"10386_CR45","doi-asserted-by":"crossref","unstructured":"Ona, G., M. Kohek, and J.C. Bouso. 2022. The illusion of knowledge in the emerging field of psychedelic research. New Ideas in Psychology 67: 67100967.","DOI":"10.1016\/j.newideapsych.2022.100967"},{"issue":"3","key":"10386_CR46","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0957154X16648822","volume":"27","author":"M Oram","year":"2016","unstructured":"Oram, M. 2016. Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration. History of Psychiatry 27(3): 290\u2013306:","journal-title":"History of Psychiatry"},{"key":"10386_CR47","doi-asserted-by":"crossref","unstructured":"Owen, R., J. Stilgoe, P. Macnaughten, M. Gorman, E. Fisher and D. Guston. 2013. A Framework for Responsible Innovation. In Responsible Innovation: Managing the Responsible Emergence of Science and Innovation in Society, edited by R. Owen, J. Bessant, and M. Heintz, 27\u201350.","DOI":"10.1002\/9781118551424.ch2"},{"key":"10386_CR48","doi-asserted-by":"publisher","first-page":"743599","DOI":"10.3389\/fpsyt.2021.743599","volume":"12","author":"LA Page","year":"2021","unstructured":"Page, L.A., A. Rehman, H. Syed, K. Forcer, and G. Campbell. 2021. The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Frontiers in Psychiatry 12: 743599.","journal-title":"Frontiers in Psychiatry"},{"key":"10386_CR49","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","volume":"11","author":"R Petranker","year":"2020","unstructured":"Petranker, R., T. Anderson, and N. Farb. 2020. Psychedelic research and the need for transparency: Polishing Alice\u2019s looking glass.\u00a0Frontiers in Psychology 11: 1681.","journal-title":"Frontiers in Psychology"},{"issue":"3","key":"10386_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamapsychiatry.2021.3972","volume":"79","author":"J Phelps","year":"2022","unstructured":"Phelps, J., R.N. Shah, and J.A. Lieberman. 2022. The rapid rise in investment in psychedelics\u2014cart before the horse. JAMA Psychiatry 79(3): 189\u2013190.","journal-title":"JAMA Psychiatry"},{"key":"10386_CR51","volume-title":"How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence","author":"M Pollan","year":"2018","unstructured":"Pollan, M. 2018. How to change your mind: What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. London: Penguin Press."},{"issue":"1","key":"10386_CR52","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/0963662513497324","volume":"23","author":"H Riesch","year":"2013","unstructured":"Riesch, H., and C. Potter. 2013. Citizen science as seen by scientists: Methodological, epistemological and ethical dimensions. Public Understanding of Science 23(1): 107\u2013120.","journal-title":"Public Understanding of Science"},{"issue":"12","key":"10386_CR53","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S., A. Bossis, J. Guss, et al. 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology 30(12): 1165\u20131180.","journal-title":"Journal of Psychopharmacology"},{"issue":"7","key":"10386_CR54","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1177\/00048674231172691","volume":"57","author":"SL Rossell","year":"2023","unstructured":"Rossell, S.L., S.E. Meikle, M.L. Williams, and D.J. Castle. 2023. Why didn\u2019t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? Australian and New Zealand Journal of Psychiatry 57(7): 933\u20131081.","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"12","key":"10386_CR55","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJ Rucker","year":"2016","unstructured":"Rucker, J.J., L.A. Jelen, S. Flynn, K.D. Frowde, and A.H. Young. 2016. Psychedelics in the treatment of unipolar mood disorders: A systematic review.\u00a0Journal of Psychopharmacology 30(12): 1220\u20131229.","journal-title":"Journal of Psychopharmacology"},{"key":"10386_CR56","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders, B., J. Sim, T. Kingstone, et al. 2018. Saturation in qualitative research: Exploring its conceptualization and operationalization. Quality and Quantity 52: 1893\u20131907.","journal-title":"Quality and Quantity"},{"key":"10386_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12961-020-0528-9","volume":"18","author":"P Slattery","year":"2020","unstructured":"Slattery, P., A.K. Saeri, and P. Bragge. 2020. Research co-design in health: A rapid overview of reviews. Health Research Policy and Systems 18: 17.","journal-title":"Health Research Policy and Systems"},{"key":"10386_CR58","doi-asserted-by":"publisher","first-page":"774736","DOI":"10.3389\/fpsyt.2021.774736","volume":"12","author":"DT Smith","year":"2022","unstructured":"Smith, D.T., S.C. Faber, N.T. Buchanan, D. Foster, and L. Green. 2022. The need for psychedelic-assisted therapy in the black community and the burdens of its provision. Frontiers in Psychiatry 12: 774736.","journal-title":"Frontiers in Psychiatry"},{"key":"10386_CR59","doi-asserted-by":"publisher","first-page":"109165","DOI":"10.1016\/j.neuropharm.2022.109165","volume":"216","author":"WR Smith","year":"2022","unstructured":"Smith, W.R., and P.S. Appelbaum. 2022. Novel ethical and policy issues in psychiatric uses of psychedelic substances.\u00a0Neuropharmacology 216: 109165.","journal-title":"Neuropharmacology"},{"key":"10386_CR60","first-page":"807","volume":"41","author":"WR Smith","year":"2020","unstructured":"Smith, W.R., and D. Sisti. 2020. Ethics and ego dissolution: The case of psilocybin.\u00a0Journal of Medical Ethics 41: 807\u2013814.","journal-title":"Journal of Medical Ethics"},{"key":"10386_CR61","doi-asserted-by":"publisher","first-page":"1119115","DOI":"10.3389\/fpsyg.2023.1119115","volume":"14","author":"MJ Spriggs","year":"2023","unstructured":"Spriggs, M.J., A. Murphy-Beiner, R. Murphy, J. Bornemann, H.Thurgur, and A.K. Schlag. 2023. ARC: a framework for access, reciprocity and conduct in psychedelic therapies. Frontiers in Psychology 14: 1119115.","journal-title":"Frontiers in Psychology"},{"issue":"2","key":"10386_CR62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/23299460.2021.1955613","volume":"8","author":"BC Stahl","year":"2021","unstructured":"Stahl, B.C., S. Akintoye, L. Bitsch, et al. 2021. From responsible research and innovation to responsibility by design. Journal of Responsible Innovation 8(2): 175\u2013198.","journal-title":"Journal of Responsible Innovation"},{"issue":"9","key":"10386_CR63","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.respol.2013.05.008","volume":"42","author":"J Stilgoe","year":"2013","unstructured":"Stilgoe, J., R. Owen, and P. Macnaghten. 2013. Developing a framework for responsible innovation.\u00a0Research Policy\u00a042(9): 1568\u20131580.","journal-title":"Research Policy"},{"issue":"4","key":"10386_CR64","first-page":"107262","volume":"48","author":"D Strauss","year":"2021","unstructured":"Strauss, D., S. de la Salle, J. Sloshower, and M.T. Williams. 2021. Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal of Medical Ethics 48(4): 107262.","journal-title":"Journal of Medical Ethics"},{"key":"10386_CR65","unstructured":"Therapeutic Goods Administration [TGA]. 2021. Notice of final decision to not amend the current Poisons Standard -Psilocybin and MDMA. December 15. https:\/\/www.tga.gov.au\/sites\/default\/files\/notice-final-decisions-amend-or-not-amend-current-poisons-standard-relation-psilocybin-and-mdma.pdf. Accessed July 31, 2023."},{"key":"10386_CR66","unstructured":"Therapeutic Goods Administration [TGA]. 2023. Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. February 3. https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists. Accessed July 31, 2023."},{"issue":"6","key":"10386_CR67","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong, A., P. Sainsbury, and J. Craig. 2007. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Healthcare 19(6): 349\u2013357.","journal-title":"International Journal for Quality in Healthcare"},{"issue":"12","key":"10386_CR68","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/jme-2022-108816","volume":"49","author":"D Villiger","year":"2023","unstructured":"Villiger, D., and M. Trachsel. 2023. With great power comes great vulnerability: An ethical analysis of psychedelics\u2019 therapeutic mechanisms proposed by the REBUS hypothesis. Journal of Medical Ethics 49(12): 826\u2013832.","journal-title":"Journal of Medical Ethics"},{"key":"10386_CR69","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/9781118551424.ch3","volume-title":"Responsible innovation: Managing the responsible emergence of science and innovation in society","author":"R von Schomberg","year":"2013","unstructured":"von Schomberg, R. 2013. A vision of responsible innovation. In Responsible innovation: Managing the responsible emergence of science and innovation in society, edited by R. Owen, J. Bessant, and M. Heintz, 51\u201374. Chichester: Wiley."},{"key":"10386_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11569-020-00365-5","volume":"14","author":"S W\u00e4scher","year":"2020","unstructured":"W\u00e4scher, S., N. Biller-Andorno, and A. Deplazes-Zemp. 2020. \u201cI don\u2019t want to do anything bad.\u201d Perspectives on scientific responsibility: Results from a qualitative interview study with senior scientists. Nanoethics 14: 135\u2013153.","journal-title":"Nanoethics"},{"issue":"8","key":"10386_CR71","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jamapsychiatry.2022.1619","volume":"79","author":"A Wexler","year":"2022","unstructured":"Wexler, A., and D. Sisti. 2022. Brain wellness \u201cspas\u201d\u2014Anticipating the off-label promotion of psychedelics. JAMA Psychiatry 79(8): 748\u2013749. http:\/\/jamanetwork.com\/article.aspx?doi=https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.1619","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10386_CR72","first-page":"279","volume":"7","author":"SW Wheeler","year":"2020","unstructured":"Wheeler, S.W., and N.L. Dyer. 2020. A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future.\u00a0Psychology of Consciousness: Theory, Research, and Practice 7(3): 279\u2013315.","journal-title":"Psychology of Consciousness: Theory, Research, and Practice"},{"key":"10386_CR73","doi-asserted-by":"publisher","first-page":"737738","DOI":"10.3389\/fpsyt.2021.737738","volume":"12","author":"ML Williams","year":"2021","unstructured":"Williams, M. L., D. Korevaar, R. Harvey, et al. 2021. Translating psychedelic therapies from clinical trials to community clinics: Building bridges and addressing potential challenges ahead. Frontiers in Psychiatry 12: 737738.","journal-title":"Frontiers in Psychiatry"},{"issue":"8","key":"10386_CR74","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/ijnp\/pyab026","volume":"24","author":"DB Yaden","year":"2021","unstructured":"Yaden, D.B., M.W. Johnson, R.R. Griffiths, et al. 2021a. Psychedelics and consciousness: Distinctions, demarcations, and opportunities.\u00a0The International Journal of Neuropsychopharmacology\u00a024(8): 615\u2013623.","journal-title":"The International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10386_CR75","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","volume":"78","author":"DB Yaden","year":"2021","unstructured":"Yaden, D.B., M.E. Yaden, and R.R. Griffiths. 2021b. Psychedelics in psychiatry\u2014Keeping the renaissance from going off the rails. JAMA Psychiatry 78(5): 469\u2013470.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10386_CR76","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","volume":"79","author":"DB Yaden","year":"2022","unstructured":"Yaden, D.B., J.B. Potash, and R.R. Griffiths. 2022. Preparing for the bursting of the psychedelic hype bubble.\u00a0JAMA Psychiatry 79(10): 943\u2013944.","journal-title":"JAMA Psychiatry"}],"container-title":["Journal of Bioethical Inquiry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11673-024-10386-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11673-024-10386-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11673-024-10386-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:38:10Z","timestamp":1757119090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11673-024-10386-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10386"],"URL":"https:\/\/doi.org\/10.1007\/s11673-024-10386-4","relation":{},"ISSN":["1176-7529","1872-4353"],"issn-type":[{"value":"1176-7529","type":"print"},{"value":"1872-4353","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.The study did not require direct funding, and no funding organisations were involved in any stage of the research, manuscript writing, or decision to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}